
|Videos|September 25, 2017
Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian Cancer
Author(s)Douglas A. Levine, MD
Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the efficacy of niraparib (Zejula) on progression-free survival in patients with recurrent ovarian cancer with partial response to the last platinum-based chemotherapy.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: Lung Cancer Advancements and FDA Decisions
2
Nivolumab Outperforms Brentuximab Vedotin in PFS in Classic Hodgkin Lymphoma
3
Savolitinib/Osimertinib Extends PFS in MET-Amplified EGFR-Mutated NSCLC
4
Second-Line Therapy and Ruxolitinib for cGVHD
5













































